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Thecytokine cachectin/tumor necrosis factor (cachectin/TNF) plays a pivotal role
in the pathophysiologic consequences of severe infection, and is a mediator of fatal
bacteremic shock (reviewed in references 1, 2). Infusions ofrecombinantcachetin/TNF
induce cardiovascular shock, hemorrhagic necrosis in tissues, and metabolic de-
rangements similar to both experimental endotoxemia and clinical septic shock (3,
4) . Anti-cachectin/TNF antibodies protect mice (5) and rabbits (6) from otherwise
lethal endotoxemia, and prevent the development of lethal septic shock syndrome
during overwhelming experimental bacteremia in baboons (7) . Moreover, high con-
centrations of circulating cachectin/TNF correlate with lethal outcome in critically
ill patients with meningococcal infection (8), infectious purpura (9), or burn injury-
associated septicemia (10) .
Two other cytokines, IL-1 and IL-6, have also been implicated in the pathophysi-
ology ofinjury andinfection (11-13) . IL-1 and IL-6 can be detected in the circulation
of patients with active infection or endotoxemia (14-16), and administration of IL-1
or IL-6 induces some of the characteristic physiological derangements associated
with injury (17, 18), including fever and acute-phase protein responses . The recent
availability ofsensitiveand specific assays forIL-1 and IL-6prompted us to measure
the concentrations of these cytokines in stored plasma samples obtained in a previ-
ously reported series of lethal, experimental bacteremic challenges in baboons (7).
The current report demonstrates that gram-negative bacteremia induces rapid and
marked increases in circulating IL-10 and IL-6 . Moreover, passive immunization
against cachectin/TNF attenuates theappearance ofIL-10 and IL-6, suggesting that
cachectin/TNF is an essential stimulus for the release ofthese other cytokines during
septic shock syndrome .
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Materials and Methods
Experimental Protocol.
￿
The experimental protocol was reviewed and approved by the In-
stitutional Animal Care and Use Committee ofthe New York Hospital-Cornell Medical Center
(NYH-CMC). Female Papio anubis baboons (Charles River Primate Center, Port Jefferson,
NY), free of infections and parasites, were housed in the animal care facility of the NYH-
CMC. After a 12-h overnight fast, general anesthesia (sodium pentobarbital) was administered
to the animals and maintained throughout the study period as previously described (7).
All animals received an intra-aortic infusion of Escherichia coli 086:B7 (1.2 t 0.3 x 101 '
live bacteria/kg body weight) over 30 min (19). Individual baboons were randomized to one
ofthree pretreatment groups: (a) animals receiving anti-cachectin/TNF antibodies (10 mg/kg)
1 hour before the bacterial infusion (Ab -1 h), n = 3; (b) animals receiving anti-cachectin/TNF
antibodies (10 mg/kg) 2 h before the bacterial infusion (Ab -2 h), n = 3; and (c) control
animals receiving saline infusions 1 h (n = 3) or 2 h (n = 3) before bacterial infusion. Ar-
terial blood samples collected before and periodically for 8 h after bacterial challenge were
assayed for cytokine levels and metabolic substrate concentrations. Plasma samples had been
collected in heparinized tubes, centrifuged at 40C, frozen immediately, and stored at -70'C
until analysis.
Cachectin/TNFAntibody.
￿
Anti-cachectin/TNF mAbs were prepared as previously described
(7). F(ab')2 fragments were prepared by pepsin digestion of IgG (20), and purified by Mono
Q(Pharmacia Fine Chemicals, Piscataway, NJ) column chromatography. Anti-cachectin/TNF
antibodies at a concentration of 10 Pg/ml neutralized at least 50 ng/ml ofrecombinant human
cachectin/TNF (101 U/mg) as assayed by L929 cell cytotoxicity assay (21). Antibodies were
diluted in 0.917o saline and infused over a period of 30 min. The LPS content of the antibody
preparation was <0.25 ng/mg as assayed by the Limulus amebocyte lysate test.
IL-I Assay.
￿
Concentrations of IL-la and IL-lei in thawed plasma samples were assayed
by two-site ELISA using mAbs specific for each protein (22). The lower limit for detecting
IL-1a is 36 pg/ml while that for IL-10 is 15 pg/ml. Baboon plasma does not inhibit the detec-
tion of exogenously added IL-1 in either assay.
IL-6Assay.
￿
IL-6 activity in plasma samples was measured by a B.9 hybridoma prolifera-
tion assay (23). Briefly, serial dilutions of thawed plasma were incubated in triplicate with
2,000 B.9 cells for 84 h in 96-well microtiter plates. MTT (3-[4,5-dimethyl-thiazol-2-yl[2,5-
diphenyltetrazolium bromide) (300 ug/ml) was added; 3 h later the supernatant was removed
and the cells were lysed with isopropanol-0.004 N HCI. Cell proliferation was estimated
colorimetrically in an ELISA plate reader (570, 690 nm). One B.9 hybridoma growth unit
was defined as the quantity ofdiluted plasma required to produce one-halfmaximal prolifer-
ation. Values for each sample were calculated by interpolation from three or four dilutions.
Recombinant human cachetin/TNF and recombinant human IL-1/3have no proliferative effects
in this assay. B.9 cell proliferation was not affected by as much as 10 wg/ml cachectin/TNF
antibody in vitro. Inhibition by antiserum specific for human IL-6 verified specificity of this
assay. The lower limit for detecting IL-6 by this assay is 50 U/ml.
Metabolic Parameters.
￿
Plasma glucose concentrations were determined using an automated
glucose analyzer (No. 23A; Yellow Springs Instrument Co., Yellow Springs, Ohio) using the
glucose oxidase reaction (24). Plasma triglyceride concentrations were determined enzymat-
ically (25).
StatisticalAnalysis.
￿
All data are expressed as means t SEM. Two-way ANOVA and New-
man-Kuels' tests were used in statistical analysis.
Results and Discussion
We have previously reported that the appearance of circulating cachectin/TNF
in this primate model of septic shock is monophasic, peaking 1.5 h after bacterial
challenge (7). The results ofthe current report demonstrate that two other cytokines,
IL-10 and IL-6 also exhibit distinct and reproducible patterns of appearance during
infection. Circulating IL-1/3, appearing slightly later than cachectin/TNF, was de-
tectable by 2 h and peaked 3 h after the bacterial infusion (Fig. 1). Circulating IL-6,FONG ET AL.
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FIGURE 1.
￿
Circulating IL-1ft levels during experimental bacteremia. Assayfor IL-1j3 was per-
formed on plasma obtained before (t = 0) andafterE. coli infusions. Animalsimmunized against
cachectin/TNFreceived anti-cachectin/TNF mAbs 1 h[Ab(-1 h)] or 2h[Ab(-2 h)] before bac-
terial challenge.
appearing even later, was detectable within 3 h, and continued to rise throughout
the 8-h study period (Fig. 2).
In cultured macrophages and othercells, and in experimental animals, exposure
to recombinant cachectin/TNF induces the biosynthesis of IL-1 and IL-6 (11, 13,
time (hr) sp(0.05 vs t=0
tp<0.05 vs control
time (hr)
￿
,p<O.05 vs t=0
tp<0.05 vs control
FIGURE 2.
￿
Circulating IL-6 levels during experimental bacteremia. Assay for IL-6 was per-
formed on plasmaobtained before (t = 0) andafterE. coli infusions. Experimental animalswere
immunized against cachectin/TNF as described in Fig. 1.1630
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26), andthese factorshave been implicated as secondarymediatorsofthepathophysio-
logicaleffects ofcachectin/TNF Thepresentdata indicate that during overwhelming
infection, cachectin/TNF secretion preceded the production ofIL-1S, andIL-6, and
was a necessary stimulus for their release in vivo. Pretreatment with anti-cachec-
tin/TNF antibodies significantly attenuated the circulating IL-10 response (p <0.006)
(Fig. 1). Comparisonsbetweenpeak IL-10 levels were particularly noteworthy (con-
trol: 2.5 t 1.1 ng/ml; Ab (-1 h): 1.4 t 0.5; Ab (-2 h): 0.3 t 0.2). Pretreatment
with anti-cachectin/TNF antibodies also attenuated the IL-6 response to bacterial
challenge (p < 0.004) (t = 8; control: 17 t 6 x 103 U/ml; Ab (-1 h): 6 t 6 x
103; Ab (-2 h): 0.9 t 0.8 x 103) (Fig. 2). Considering that bacterial LPS is itself
a potent stimulus for IL-1 and IL-6 release in vitro (12, 13), the observation that
specific neutralization of cachectin/TNF significantly reduced appearance of IL-10
and IL-6 during overwhelming gram-negative bacteremia is striking.
No detectable IL-la was found in the circulation at any time point in any group
despite theproduction oflargequantities of IL-1(3. This is consistent with theobser-
vation that IL-10 is the predominate form ofIL-1 produced by activated monocytes
(27). Since IL-1 and cachectin/TNF can induce the biosynthesis of IL-6, and the
peak IL-1 levelin thecirculation precedes that ofIL-6, it cannot be determined from
the present study whether the attenuation of IL-6 is a direct or indirect effect of
neutralizing cachectin/TNF Peak IL-6 levels correlate well with peak IL-10 responses
in the current experiment (r = 0.87, data not shown), so it is possible that the re-
duced appearance of IL-6 was due in part to reduction of the earlier IL-1 response.
Further studies with antibodies against IL-10 may resolve the question.
The overwhelming dose of live E. coli used in the current experiment caused a
rapidly fatal syndrome in nonimmunized control animals that is likely attributable
to tissue effects of cachectin/TNF Previously we reported that the earlier (-2 h)
antibody treatment was more effective in preventing septic shock and mortality(7).
We now report that anti-cachectin/TNF antibodies given 2 h before bacterial chal-
lenge aresignificantlymore effective in attenuatingIL-10and IL-6 appearance than
antibodies administered only 1 hbefore E. coli. 2-hpretreatment wasalso more effective
in reducing hypoglycemia and hypertriglyceridemia, which arecharacteristic meta-
bolic sequelae of severe infections (Fig. 3). Improved biologic outcome might well
reflect superior tissue distribution and penetration with earlier antibody adminis-
tration. Inability to completely prevent mortality, cytokine production, and meta-
bolic derangements in the -1 h group might be attributed to incomplete neutraliza-
tion ofthelargeamounts ofcachectin/TNF produced and acting in tissues in response
to this overwhelming bacteremia. With less severe bacteremic challenge, improved
survival and hemodynamic stability are observed when anti-cachectin/TNF anti-
bodies areadministered even 30 min afterinfusion oflesserquantities ofbacteria (28).
That cachectin/TNF elicits IL-1/3 and IL-6 release in infection further empha-
sizes thepivotal role of cachectin/TNF as a mediator of septicemia and septic shock
syndrome. The lethality of cachectin/TNF is synergistically enhanced by even low
concentrations ofIL-1 (29), so that stimulation ofIL-1 biosynthesis by cachectin/TNF
serves to amplify cachectin/TNFmediated shock and tissue injury. Further studies
are necessary to determine the precise molecular and cellular mechanisms of
cachectin/TNFmediated cytokine release. The current data nevertheless demon-
strate that cachectin/TNF is a major determinant in the complex pathogenesis of0
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FIGURE 3.
￿
Anti-cachectin/TNF antibodies prevent
the hypoglycemia and hypertriglyceridemia of bac-
teremia. Arterial glucose and triglyceride levels were
measured at baseline (BL, before bacterial infusion)
and 8 h after E. coli. 'p < 0.05 vs. t = 0, 'p < 0.05
vs. control.
septic shock syndrome, not only through its direct toxicity, but also as a proximal
mediator capable of inducing a cascade of other humoral factors.
Summary
Cytokines secreted in response to invading micro-organisms are important medi-
ators ofdetrimental hemodynamic and metabolic changes in the host. To test whether
cachectin/TNF plays a role in triggering release of other cytokines in the setting
of infection, anesthetized baboons were passively immunized against systemic
cachectin/TNF before infusion of a LDtoo dose of live Escherichia coli. Bacteremia
led to significant increases in circulating levels of cachectin/TNF, IL-10, and IL-6.
Although bacterial endotoxin/lipopolysaccharide is a potent stimulus for the syn-
thesis and release of IL-1 and IL-6 in vitro, specific neutralization of cachectin/TNF
in vivo with mAb pretreatment significantly attenuated both the IL-10 and the IL-6
responses despite fulminant overwhelming bacteremia. These data suggest that
cachectin/TNF is essential for the initiation or amplification of IL-1 and IL-6 re-
lease during lethal gram-negative septic shock syndrome.
Receivedforpublication 29 June 1989.
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